News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
716,300 Results
Type
Article (40760)
Company Profile (269)
Press Release (675268)
Multimedia
Podcasts (82)
Webinars (17)
Section
Business (204610)
Career Advice (2018)
Deals (35512)
Drug Delivery (105)
Drug Development (81420)
Employer Resources (173)
FDA (16357)
Job Trends (14935)
News (346243)
Policy (32755)
Tag
Academia (2564)
Accelerated approval (18)
Adcomms (25)
Allergies (122)
Alliances (49582)
ALS (142)
Alzheimer's disease (1590)
Antibody-drug conjugate (ADC) (243)
Approvals (16495)
Artificial intelligence (438)
Autoimmune disease (105)
Automation (32)
Bankruptcy (361)
Best Places to Work (11644)
BIOSECURE Act (20)
Biosimilars (160)
Biotechnology (175)
Bladder cancer (136)
Brain cancer (49)
Breast cancer (518)
Cancer (4110)
Cardiovascular disease (342)
Career advice (1700)
Career pathing (33)
CAR-T (238)
CDC (45)
Cell therapy (635)
Cervical cancer (32)
Clinical research (68647)
Collaboration (1392)
Company closure (4)
Compensation (977)
Complete response letters (46)
COVID-19 (2771)
CRISPR (80)
C-suite (626)
Cystic fibrosis (133)
Data (5192)
Decentralized trials (2)
Denatured (24)
Depression (104)
Diabetes (443)
Diagnostics (6572)
Digital health (38)
Diversity (11)
Diversity, equity & inclusion (45)
Drug discovery (200)
Drug pricing (162)
Drug shortages (28)
Duchenne muscular dystrophy (202)
Earnings (89684)
Editorial (50)
Employer branding (21)
Employer resources (151)
Events (116142)
Executive appointments (931)
FDA (18946)
Fibrodysplasia Ossificans Progressiva (4)
Friedreich's ataxia (6)
Frontotemporal dementia (20)
Funding (1264)
Gene editing (176)
Generative AI (34)
Gene therapy (511)
GLP-1 (898)
Government (4655)
Grass and pollen (6)
Guidances (373)
Healthcare (18871)
HIV (47)
Huntington's disease (38)
IgA nephropathy (71)
Immunology and inflammation (222)
Immuno-oncology (22)
Indications (65)
Infectious disease (3011)
Inflammatory bowel disease (177)
Inflation Reduction Act (13)
Influenza (100)
Intellectual property (199)
Interviews (315)
IPO (16621)
IRA (49)
Job creations (3641)
Job search strategy (1428)
Kidney cancer (15)
Labor market (78)
Layoffs (543)
Leadership (28)
Legal (7952)
Liver cancer (87)
Longevity (12)
Lung cancer (588)
Lymphoma (298)
Machine learning (32)
Management (59)
Manufacturing (632)
MASH (151)
Medical device (13661)
Medtech (13696)
Mergers & acquisitions (19816)
Metabolic disorders (1108)
Multiple sclerosis (138)
NASH (16)
Neurodegenerative disease (235)
Neuropsychiatric disorders (61)
Neuroscience (2618)
NextGen: Class of 2025 (6520)
Non-profit (4496)
Now hiring (60)
Obesity (511)
Opinion (243)
Ovarian cancer (145)
Pain (157)
Pancreatic cancer (180)
Parkinson's disease (240)
Partnered (29)
Patents (423)
Patient recruitment (350)
Peanut (53)
People (58417)
Pharmaceutical (63)
Pharmacy benefit managers (25)
Phase I (21371)
Phase II (30213)
Phase III (22543)
Pipeline (3380)
Policy (261)
Postmarket research (2565)
Preclinical (9125)
Press Release (64)
Prostate cancer (205)
Psychedelics (45)
Radiopharmaceuticals (258)
Rare diseases (638)
Real estate (5944)
Recruiting (69)
Regulatory (23717)
Reports (51)
Research institute (2371)
Resumes & cover letters (351)
Rett syndrome (20)
RNA editing (12)
RSV (76)
Schizophrenia (130)
Series A (201)
Series B (156)
Service/supplier (11)
Sickle cell disease (78)
Special edition (20)
Spinal muscular atrophy (151)
Sponsored (36)
Startups (3607)
State (2)
Stomach cancer (15)
Supply chain (97)
Tariffs (79)
The Weekly (56)
Vaccines (975)
Venture capital (69)
Weight loss (331)
Women's health (65)
Worklife (17)
Date
Today (100)
Last 7 days (568)
Last 30 days (3464)
Last 365 days (30374)
2025 (27995)
2024 (35250)
2023 (40091)
2022 (51204)
2021 (55764)
2020 (54123)
2019 (46543)
2018 (35022)
2017 (32119)
2016 (31486)
2015 (37553)
2014 (31318)
2013 (26349)
2012 (28570)
2011 (29263)
2010 (27329)
Location
Africa (737)
Alabama (74)
Alaska (7)
Arizona (281)
Arkansas (13)
Asia (38805)
Australia (6348)
California (10017)
Canada (2979)
China (906)
Colorado (419)
Connecticut (437)
Delaware (284)
Europe (83723)
Florida (1482)
Georgia (320)
Hawaii (2)
Idaho (61)
Illinois (747)
India (51)
Indiana (474)
Iowa (19)
Japan (336)
Kansas (122)
Kentucky (35)
Louisiana (24)
Maine (70)
Maryland (1282)
Massachusetts (7239)
Michigan (293)
Minnesota (565)
Mississippi (5)
Missouri (117)
Montana (30)
Nebraska (26)
Nevada (106)
New Hampshire (73)
New Jersey (2718)
New Mexico (28)
New York (2677)
North Carolina (1320)
North Dakota (8)
Northern California (4760)
Ohio (295)
Oklahoma (20)
Oregon (37)
Pennsylvania (2075)
Puerto Rico (19)
Rhode Island (44)
South America (1101)
South Carolina (55)
South Dakota (1)
Southern California (3872)
Tennessee (157)
Texas (1532)
United States (35894)
Utah (298)
Vermont (1)
Virginia (232)
Washington D.C. (78)
Washington State (814)
West Virginia (4)
Wisconsin (85)
Wyoming (2)
716,300 Results for "moderna inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Pipeline
Moderna Cans 3 mRNA Vaccines, Secures $1.5B Loan in Quest for 10% Growth
Amid an aggressive savings push, Moderna has cut three assets and taken on a loan to increase “flexibility.”
November 21, 2025
·
2 min read
·
Tristan Manalac
Cancer
Moderna Claims Early Victory for Cancer Antigen in Melanoma
Moderna’s mRNA-4359, when used with Keytruda, achieves a 24% overall objective response rate in patients with melanoma, with efficacy increasing to 67% in those positive for PD-L1.
October 13, 2025
·
2 min read
·
Tristan Manalac
Vaccines
Moderna Scraps CMV Vaccine After Phase III Fail
A key question for investors going forward will be whether Moderna’s other latent virus vaccines for Epstein-Barr and shingles can succeed after the failure of the CMV program.
October 23, 2025
·
3 min read
·
Tristan Manalac
Earnings
Moderna’s Bancel Nay on M&A, Yay on R&D Partnerships
It’s not often that a CEO outright dismisses M&A prospects, but Moderna CEO Stéphane Bancel says the mRNA biotech has enough programs on its hands.
August 1, 2025
·
4 min read
·
Annalee Armstrong
Patents
Moderna Wins UK Patent Battle Against Pfizer and BioNTech
A U.K. Court of Appeals ruling confirms the validity of a patent covering modifications of mRNA used in Moderna’s vaccines.
August 1, 2025
·
2 min read
·
Dan Samorodnitsky
COVID-19
Vinay Prasad Overruled Reviewers on Moderna’s COVID-19 Shot for Kids
In a July 9 memo, the director of the FDA’s Center for Biologics Evaluation and Research contended there was not enough evidence that the benefits of Moderna’s COVID-19 vaccine Spikevax outweighed its risks in healthy children.
July 16, 2025
·
2 min read
·
Tristan Manalac
Influenza
Moderna’s Promised mRNA Flu Vaccine Bests Current Standard Shot
In adults 50 and older, Moderna’s flu shot was more than 26% better than an unspecified commercial vaccine. In May, the company pulled its application for a combo flu/COVID-19 shot, saying it would refile following data from this Phase III trial.
June 30, 2025
·
2 min read
·
Tristan Manalac
Layoffs
Moderna Slashes Global Workforce by 10% as $1.5B Cost Cuts Hit Home
The announced reduction of hundreds of staff came a day ahead of Moderna’s Q2 earnings report.
July 31, 2025
·
1 min read
·
Annalee Armstrong
COVID-19
Moderna Wins Full Approval for COVID-19 Shot for Higher-Risk Kids
The approval of Moderna’s Spikevax for kids at higher risk of contracting the disease continues the company’s regulatory winning streak, which has also included nods for a next-gen COVID-19 vaccine and an RSV shot.
July 11, 2025
·
2 min read
·
Tristan Manalac
Vaccines
ACIP Skips Votes on COVID and Moderna’s mRESVIA but Scrutinzes mRNA Vaccine Safety
The revamped and “more anti-vax skewed ACIP committee” at the CDC “has a bone to pick with mRNA vaccines,” according to Truist Securities analysts. Meanwhile, the FDA moves forward on having Pfizer/BioNTech and Moderna update labels for their COVID vaccines.
June 27, 2025
·
2 min read
·
Jef Akst
1 of 71,630
Next
